Compile Data Set for Download or QSAR
Report error Found 54 of ic50 data for polymerid = 548
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataIC50: 0.00200nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataIC50: 0.00200nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 0.00900nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50: 0.00900nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50: 0.00900nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538658(NCGC 00249373 | US11254667, Compound I-17 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397417(US9987278, Compound Reference 27)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397280(US9987278, Compound Reference 2)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397418(US9987278, Compound Reference 28)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397419(US9987278, Compound Reference 29)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397420(US9987278, Compound Reference 30)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397422(US9987278, Compound Reference 32)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397424(US9987278, Compound Reference 34)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397425(US9987278, Compound Reference 35)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397426(US9987278, Compound Reference 36)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397427(US9987278, Compound Reference 37)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397428(US9987278, Compound Reference 38)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
In DepthDetails
US Patent
PDB3D3D Structure (crystal)
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397429(US9987278, Compound Reference 39)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397430(US9987278, Compound Reference 40)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397431(US9987278, Compound Reference 41)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397415(US9987278, Compound Reference 25)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397395(US9987278, Compound Reference 5)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397397(US9987278, Compound Reference 7)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397399(US9987278, Compound Reference 9)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397400(US9987278, Compound Reference 10)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397404(US9987278, Compound Reference 14)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397406(US9987278, Compound Reference 16)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397407(US9987278, Compound Reference 17)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397408(US9987278, Compound Reference 18)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397410(US9987278, Compound Reference 20)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397411(US9987278, Compound Reference 21)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397412(US9987278, Compound Reference 22)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397416(US9987278, Compound Reference 26)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397409(US9987278, Compound Reference 19)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397413(US9987278, Compound Reference 23)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397414(US9987278, Compound Reference 24)
Affinity DataIC50: 1nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397421(US9987278, Compound Reference 31)
Affinity DataIC50: 5.5nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397232(US9987278, Compound Reference 1)
Affinity DataIC50: 5.5nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397393(US9987278, Compound Reference 3)
Affinity DataIC50: 5.5nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397394(US9987278, Compound Reference 4)
Affinity DataIC50: 5.5nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397396(US9987278, Compound Reference 6)
Affinity DataIC50: 5.5nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397398(US9987278, Compound Reference 8)
Affinity DataIC50: 5.5nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397401(US9987278, Compound Reference 11)
Affinity DataIC50: 5.5nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM397402(US9987278, Compound Reference 12)
Affinity DataIC50: 5.5nMAssay Description:Quizartinib (Ambit Biosciences Corporation) was used as Reference Compound 1.6 μL (0.75 ng) of a mutant FLT3 protein (FLT3 D835Y, Life Technolog...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

Displayed 1 to 50 (of 54 total ) | Next | Last >>
Jump to: